Summary
The recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommending to grant a marketing authorisation for Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
Analysis
The potential approval of Iressa in advanced NSCLC with activating mutations of EGFR-TK will represent an option in the therapeutic strategy of this disease.
But if is a real new option or if it replaces a competitor in selected patients...that remains to be seen! Finally on the basis of technical (analysis of the mutational status) and economical (costs of the drug and of the above mentioned procedure) aspects we will make our choice...
Rossana Berardi consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
